Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

기사 요약

Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.